参松养心胶囊作为首个获推荐的创新中药入选该《指南》，被推荐用于阵发性房颤患者维持窦性心律及经射频消融术后的持续性房颤患者降低房颤复发 率。 2025年8月9日，《中国心房颤动管理指南(2025)》(以下简称《指南》)正式发布。 《指南》是在吸收国内外心房颤动相关指南/共识重点内容及近年来有关房颤基础与临床研究成果的基础上，经中华医学会心电生理和起搏分会、中国医 师协会心律学专业委员会和房颤中心专家委员会组织67名专家共同制定。 参松养心胶囊缘何能跻身权威学术指南？它解决了哪些临床关键痛点问题？其入选具有怎样的里程碑意义？ 权威指南引领革新，中医药获历史性推荐 房颤是临床上常见的一种心律失常。该病严重影响患者生活质量，并显著增加死亡、卒中、心力衰竭和痴呆风险。据中国房颤中心联盟流行病学调查结果 显示，目前我国房颤人群患者人数高达2000万。当前房颤治疗存在"有效药物少，长期安全性不足，术后复发率高"等痛点。面对这一全球性公共卫生挑 战，制定一部科学、规范、具有前瞻性的诊疗指南，显得尤为重要。 中华医学会心电生理和起搏分会名誉主任委员、武汉大学人民医院教授黄从新在发布会上作报告时，对《指南》的意义给予了高度评价。 ...

Apyx Medical (APYX) FY Conference August 12, 2025 04:00 PM ET Speaker0we go.Speaker1Okay. Thanks. Good afternoon, everyone, and thank you for joining us at this year's Canaccord Genuity global growth conference. My name is Caitlin Cronin, and I am on the medical device team here at Canaccord Genuity. I'm joined today by Apics Medical, a medical technology company specializing in helium plasma energy solutions for minimally invasive cosmetic and surgical procedures.With me today are, Charlie Goodwin's CEO, a ...

Core Viewpoint - The newly released "Guidelines for Percutaneous Coronary Intervention (2025)" recommends Tongxinluo capsules for the treatment of acute coronary syndrome, particularly for patients undergoing interventional therapy, highlighting its benefits in myocardial ischemia, improving no-reflow, and reducing complications [1][7]. Group 1: Triple Protective Effects of Tongxinluo - Tongxinluo has been shown to have a triple protective effect on ischemic cardiovascular and cerebrovascular diseases, supported by extensive research [2][7]. - The three protective effects include blood protection, vascular protection, and microvascular protection of ischemic tissues [4][5][6]. Group 2: Blood Protection - Tongxinluo exhibits lipid-lowering, anti-inflammatory, anticoagulant, and anti-thrombotic effects, making it a valuable addition to standard treatments like statins and aspirin [4]. - It can reduce aspirin resistance and dosage, thereby minimizing bleeding side effects [4]. Group 3: Vascular Protection - Tongxinluo effectively relieves vascular spasms and stabilizes plaques, with an 83% success rate in relieving vascular spasms [5]. - It has been recognized as the only innovative traditional Chinese medicine recommended for relieving vascular spasms in expert consensus [5]. Group 4: Microvascular Protection - After PCI, 5% to 50% of patients may experience no-reflow due to coronary microcirculation dysfunction, particularly in acute myocardial infarction cases [6]. - Tongxinluo activates eNOS to protect endothelial cells and improve microcirculation, reducing no-reflow incidence by 36.6% and enhancing myocardial recovery [6]. Group 5: Clinical Evidence and Recommendations - Tongxinluo has received over 30 national guidelines and consensus recommendations for its clinical application in treating cardiovascular diseases [13][14]. - It is particularly recommended for various stages of ischemic cardiovascular diseases, including acute coronary syndrome and stable angina [14][15]. Group 6: Research and Awards - Tongxinluo has been recognized with multiple national awards for its contributions to the treatment of coronary heart disease and related research [18]. - It has been approved for registration and sale in several countries, including Vietnam, Canada, and Singapore, demonstrating its international recognition [20].

Core Insights - The 25th Cardiology Conference and the 2025 Henan Provincial Medical Association's Academic Annual Meeting on Electrophysiology and Pacing was held in Zhengzhou, focusing on cutting-edge technologies, clinical practices, and research achievements in the field of cardiology [1][3] Group 1: Conference Overview - The conference theme was "Seeing the Future of Heart Health in Henan, Smartly Designing the City of Rhythm," featuring nearly a thousand experts and scholars from both domestic and international backgrounds [3] - Over 100 sessions were organized, covering hot topics such as pulse ablation, artificial intelligence, and the integration of medicine and engineering [3][4] Group 2: Key Discussions and Innovations - The conference emphasized the importance of talent and technological innovation as core driving forces for the development of cardiology in China, with a call for professionals to transition from "catching up" to "leading" in the field [3] - Discussions included the popularization of catheter ablation technology and the decentralization of medical resources to grassroots levels, aiming to enhance precision diagnosis and treatment of arrhythmias [4] Group 3: Future Directions - A proposal was made to integrate resources from multiple medical societies over the next decade to create a high-quality evidence-based medicine platform, promoting the widespread adoption of atrial fibrillation ablation techniques in 2,000 county hospitals [4] - The conference aimed to facilitate a systematic agenda covering basic research, clinical practice, technology transfer, and interdisciplinary collaboration, fostering deep exchanges between clinical experience and research innovation [4]

Core Viewpoint - Arrhythmia is a significant cause of mortality in cardiovascular diseases, and traditional Chinese medicine (TCM) plays an irreplaceable role in its prevention and treatment, with the product "Shensong Yangxin Capsule" being a notable example due to its strong evidence-based medical support and high recommendations in clinical guidelines [1][13]. Group 1: Clinical Research and Efficacy - The "Shensong Yangxin Capsule" was recognized in a study published in the "European Heart Journal," showing that it can reduce the risk of atrial fibrillation recurrence by 40.4% after one year in patients who underwent radiofrequency ablation [2][5]. - Six evidence-based medical studies have confirmed the efficacy of "Shensong Yangxin Capsule" in treating various arrhythmias, including premature ventricular contractions and atrial fibrillation, demonstrating its advantages in integrated regulation [4][13]. - The capsule has been shown to significantly reduce the frequency of premature ventricular contractions and improve heart function in patients with heart failure [4][6]. Group 2: Guidelines and Recommendations - Multiple expert consensus and guidelines recommend "Shensong Yangxin Capsule" for treating arrhythmias, highlighting its comparable efficacy and better safety profile compared to conventional drugs like Propafenone and Mexiletine [5][6][8]. - The capsule is the only innovative TCM recommended for symptomatic premature ventricular contractions in the "Chinese Expert Consensus on Ventricular Arrhythmias" [6][7]. - For patients with heart failure and ventricular arrhythmias, the guidelines suggest considering "Shensong Yangxin Capsule" to reduce the burden of premature ventricular contractions and improve cardiac function [7][10]. Group 3: Broader Implications and Future Prospects - "Shensong Yangxin Capsule" is positioned as an essential innovative TCM in the treatment of arrhythmias, showcasing the value of TCM in modern medicine [13]. - The ongoing development of high-quality evidence-based research is expected to further enhance the benefits of "Shensong Yangxin Capsule" for patients [13].

Core Viewpoint - The research team led by Liu Hui and Xu Chang has introduced a novel methodology called "evidence contamination," which aims to address biases in randomized controlled trials (RCTs) and improve the reliability of evidence in clinical guidelines [1][3][4]. Group 1: Research Findings - The team identified 1,300 problematic trials and tracked 847 evidence studies containing these trials, leading to the discovery that 20.6% of evidence conclusions changed when problematic trials were excluded [3][4]. - At least 157 international clinical guidelines were found to be influenced by these problematic conclusions, indicating a cascading effect on global medical evidence [3][4]. Group 2: Implications for Clinical Guidelines - The findings highlight significant discrepancies in clinical guidelines, such as those for the treatment of advanced liver cancer, where the National Comprehensive Cancer Network (NCCN) and the European Association for the Study of the Liver (EASL) have conflicting recommendations [3]. - The research emphasizes the need for a new approach to clinical guideline decision-making, as current practices may lead to serious medical adverse events due to unreliable evidence [3][4]. Group 3: Recognition and Future Directions - The research has been published in The BMJ, marking the first time an original theory from Chinese scholars has been featured in the journal's 180-year history, showcasing China's contributions to medical research methodology [1][5]. - The establishment of the Asia-Pacific Network for Evidence Analysis, Synthesis, and Translation (APN-EAST) aims to enhance global collaboration in evidence-based medicine and develop a system for assessing and preventing evidence contamination [5].

Core Concept - The article highlights the significant impact of evidence-based medicine (EBM) in transforming medical practices in China, primarily through the efforts of Wang Jiyao, who introduced and promoted EBM in the country [3][15][26]. Group 1: Introduction of Evidence-Based Medicine - Wang Jiyao was influenced by her mentor David Sackett during her studies in Canada, where she learned the importance of evidence in medical treatment [2][4]. - EBM, defined by five steps, emphasizes the necessity of using evidence rather than solely relying on personal experience in medical practices [2][3]. Group 2: Development and Promotion in China - After returning to China, Wang Jiyao translated EBM into Chinese and began promoting it, leading to significant advancements in modern medicine over nearly 30 years [3][15]. - The publication of the first EBM textbook in China in 2001 filled a gap in the field and has been revised multiple times to include updated methodologies and standards [23][24]. Group 3: Current Challenges and Future Directions - Despite the growth in clinical research and guidelines, there are concerns regarding the quality of these guidelines, with many lacking proper evaluation and facing conflicts of interest [29][31]. - The establishment of the China Clinical Practice Guidelines Alliance aims to improve the quality of clinical guidelines by uniting top experts to create reliable and practical recommendations for clinicians [33][34][41].